NEW YORK, NY – Two prominent biotechnology companies, Vertex Pharmaceuticals and CRISPR Therapeutics, both led by Indian American CEOs, have been named to TIME’s 2025 list of the 100 Most Influential ...

Kapiva, a healthcare brand focused on Ayurveda-based products, has raised $60 million in a Series D funding round. The round included $28 million in primary capital and was led by 360 ONE Asset and ...

Even amid political pressure from RFK Jr. and President Trump, as well as failed clinical data on VX-993, Vertex continues to strengthen its position in the cystic fibrosis market. Sales of its three ...

The Punjab Central Business District Development Authority (PCBDDA), commonly known as Central Business District Punjab (CBD Punjab), has taken another bold step in reshaping skyline of the Punjab's ...

Fintel reports that on September 25, 2025, Leerink Partners upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Market Perform to Outperform. Analyst Price Forecast Suggests 30.19% ...

With the business potentially at an important milestone, we thought we'd take a closer look at Vertex, Inc.'s (NASDAQ:VERX) future prospects. Vertex, Inc., together with its subsidiaries, provides ...

Get the best of CNBC Africa sent straight to your inbox with breaking business news, insights and updates from experts across the continent. Loading security verification... Get this delivered to your ...

We recently published 10 Stocks Taking the Worst Hit. Vertex Inc. (NASDAQ:VERX) is one of the worst-performing stocks on Wednesday. Vertex fell to a new 52-week low on Wednesday as investor sentiment ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising new drugs on the horizon. Vertex's price looks quite attractive, relative to ...

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported better-than-expected earnings for the second quarter after the market close on Monday. The company's revenue came in at $2.97 billion versus estimates ...

A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...